FindTrial
Sign In

Level of IgG Antibodies against Covid19 in people of Ahmedabad as on February 2021

Fourth Population Based Serosurveillance for SARS-COV2 using IgG Antibodies in Ahmedabad

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/02/031165
Enrollment
10000
Registered
2021-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Ahmedabad Municipal Corporation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Those who give written informed consent

Exclusion criteria

Exclusion criteria: any bleeding disorder, contraindication to venipuncture & hospitalized patients

Design outcomes

Primary

MeasureTime frame
Seroprevalence of IgG Antibodies against SARS-CoV-2 in general population of AhmedabadTimepoint: 1 (since this is a cross sectional study (A serosurveillance using Covid-Kavach - IgG antibody for SARS-CoV2) there is only 1 time-point)—

Secondary

MeasureTime frame
Factors Affecting IgG antibody based Immunity against SARS-CoV-2 infectionTimepoint: 1 (since this is a cross sectional study (A serosurveillance using Covid-Kavach - IgG antibody for SARS-CoV2) there is only 1 time-point)—

Countries

India

Contacts

Public ContactDr Om Prakash

Ahmedabad Municipal Corporation

dromprakash2006@gmail.com9099012740

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026